Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02820740 · ClinicalTrials.gov registry record · NA
Feasibility Study on LITT for Medical Refractory Epilepsy
A NA study, sponsored by Monteris Medical.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02820740: Clinical Trial NA study, sponsored by Monteris Medical.
NCT02820740 is a NA study that was terminated before completion, run by Monteris Medical. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02820740, a NA study, was terminated before completion, sponsored by Monteris Medical.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
Multicenter, open-label, prospective designed study to characterize the performance of brain laser interstitial thermal therapy (LITT) ablation using the Monteris NeuroBlate System for the treatment of drug-refractory medial temporal lobe epilepsy in subjects who are candidates for LITT surgery.
Primary Outcome
Characterize adverse events experienced in medial temporal lobe epilepsy subjects undergoing LITT using the NeuroBlate System. Adverse events will be collected based on subject reports and subject examination/testing.
Interventions
- DEVICE NeuroBlate System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-04-21 |
| Est. Completion | 2019-06-24 |
| Phase | NA |
Why NCT02820740 stopped before completion
NCT02820740 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which NeuroBlate System is the first listed.
NCT02820740 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02820740 about?
NCT02820740 is a clinical study titled "Feasibility Study on LITT for Medical Refractory Epilepsy". Multicenter, open-label, prospective designed study to characterize the performance of brain laser interstitial thermal therapy (LITT) ablation using the Monteris NeuroBlate System for the treatment of drug-refractory medial temporal lobe epilepsy in subjects who are candidates for LITT surgery.
What is the current status of trial NCT02820740?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2017-04-21. Estimated completion is 2019-06-24.
What interventions are being tested in trial NCT02820740?
The interventions under investigation include: NeuroBlate System (DEVICE).
Who is sponsoring clinical trial NCT02820740?
This trial is sponsored by Monteris Medical, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02820740's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI